Compared to the supernatant group or non-treatment group, “recipient cells” (both GH3 and primary pituitary adenoma cells) contacted with OCT-treated “donor cells” possess notable potent viability, GH release and less apoptosis extent in the presence of SSTA (Fig. 3g-3i, Fig. S4). The gene discussed is GH1; the disease is pituitary gland adenoma.